secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001193125-26-133346
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Therapeutics reports FY2025 net loss $12.5M; ARDS Phase 2 trial initiation in 1H 2026
--------------------------------------------------------------------------------

- Net loss FY2025 $12.5M ($2.93/sh) vs $10.8M ($2.86/sh) in FY2024; cash $13.4M at year end, plus $3.0M raised since.
- Phase 2 trial for agenT-797 in ARDS/hypoxemic pneumonia to initiate 1H 2026; early data by year end.
- GVHD program funded by NIH STTR grant and Mary Gooze award; trial launch May 2026, preliminary data 2H 2026.
- C-Further collaboration provides up to $1.1M non-dilutive funding for PRAME-TCR iNKT in pediatric oncology.
- Appointments: Dr. Terese Hammond as Head of Pulmonary; Melissa Orilall as Principal Financial Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000119312526133346/0001193125-26-133346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000119312526133346/inkt-20260331.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-133346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer